SG11202104086PA - 5-membered heteroaryl carboxamide compounds for treatment of hbv - Google Patents
5-membered heteroaryl carboxamide compounds for treatment of hbvInfo
- Publication number
- SG11202104086PA SG11202104086PA SG11202104086PA SG11202104086PA SG11202104086PA SG 11202104086P A SG11202104086P A SG 11202104086PA SG 11202104086P A SG11202104086P A SG 11202104086PA SG 11202104086P A SG11202104086P A SG 11202104086PA SG 11202104086P A SG11202104086P A SG 11202104086PA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- treatment
- membered heteroaryl
- carboxamide compounds
- heteroaryl carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748906P | 2018-10-22 | 2018-10-22 | |
| US201962858790P | 2019-06-07 | 2019-06-07 | |
| PCT/US2019/057362 WO2020086533A1 (en) | 2018-10-22 | 2019-10-22 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104086PA true SG11202104086PA (en) | 2021-05-28 |
Family
ID=68610300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104086PA SG11202104086PA (en) | 2018-10-22 | 2019-10-22 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11560370B1 (en) |
| EP (1) | EP3870296A1 (en) |
| JP (1) | JP2022508953A (en) |
| KR (1) | KR20210095143A (en) |
| CN (1) | CN113195055A (en) |
| AU (1) | AU2019364352A1 (en) |
| BR (1) | BR112021007602A2 (en) |
| CA (1) | CA3117449A1 (en) |
| IL (1) | IL282433A (en) |
| MA (1) | MA53983A (en) |
| MX (1) | MX2021004580A (en) |
| PH (1) | PH12021550887A1 (en) |
| SG (1) | SG11202104086PA (en) |
| TW (1) | TW202028190A (en) |
| WO (1) | WO2020086533A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205264A (en) * | 2020-02-25 | 2020-05-29 | 成都睿智化学研究有限公司 | Novel method for synthesizing homotopic hydroxyl and methylsulfonyl methyl compound |
| CN115916341A (en) * | 2020-04-22 | 2023-04-04 | 组装生物科学股份有限公司 | Pyrazole carboxamide compounds for the treatment of HBV |
| KR20240093580A (en) * | 2021-10-20 | 2024-06-24 | 어셈블리 바이오사이언시스, 인크. | New crystalline form |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023105481A1 (en) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
| WO2024173196A1 (en) * | 2023-02-17 | 2024-08-22 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159926A0 (en) * | 2001-08-06 | 2004-06-20 | Pharmacia Italia Spa | Aminoisoxazole derivatives active as kinase inhibitors |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| JP2010524941A (en) | 2007-04-20 | 2010-07-22 | シェーリング コーポレイション | Pyrimidinone derivatives and methods for their use |
| PE20121118A1 (en) * | 2009-05-12 | 2012-09-05 | Romark Lab Lc | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS |
| US9399619B2 (en) | 2011-07-01 | 2016-07-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| WO2013102655A1 (en) | 2012-01-06 | 2013-07-11 | Janssen R&D Ireland | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
| ES2610758T3 (en) | 2012-08-28 | 2017-05-03 | Janssen Sciences Ireland Uc | Condensed bicyclic sulfamoyl derivatives and their use as medicines in the treatment of hepatitis B |
| AR092270A1 (en) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B |
| WO2014037480A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| JP2016502519A (en) | 2012-11-09 | 2016-01-28 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Alternative use of HBV assembly effectors |
| EP2928459A4 (en) | 2012-12-06 | 2016-10-26 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| JP6409001B2 (en) | 2012-12-27 | 2018-10-17 | ドレクセル ユニバーシティ | Novel antiviral agent against HBV infection |
| PT2961732T (en) | 2013-02-28 | 2017-06-26 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| EA027068B1 (en) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JP6441315B2 (en) * | 2013-05-17 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Sulfamoylthiophenamide derivatives and their use as pharmaceuticals for treating hepatitis B |
| JP6533217B2 (en) | 2013-05-17 | 2019-06-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prevention of Hepatitis B Virus Infection |
| JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| EP3068774B1 (en) * | 2013-11-14 | 2019-12-25 | Novira Therapeutics Inc. | Azepane derivatives and methods of treating hepatitis b infections |
| EA035848B1 (en) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| WO2016149581A1 (en) * | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| CN105503730B (en) * | 2015-12-25 | 2018-06-22 | 山东大学 | Pyrazole derivatives and preparation method and application |
| JOP20180008A1 (en) * | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | Compounds for the treatment of hepatitis b virus infection |
| CN108250112B (en) * | 2018-01-30 | 2019-08-27 | 西北大学 | A kind of 1- alkyl -1- arylthio -2- (1H)-naphthalene ketone derivant and preparation method thereof |
-
2019
- 2019-10-22 BR BR112021007602-6A patent/BR112021007602A2/en unknown
- 2019-10-22 MX MX2021004580A patent/MX2021004580A/en unknown
- 2019-10-22 JP JP2021547054A patent/JP2022508953A/en active Pending
- 2019-10-22 CA CA3117449A patent/CA3117449A1/en active Pending
- 2019-10-22 TW TW108138129A patent/TW202028190A/en unknown
- 2019-10-22 US US17/287,681 patent/US11560370B1/en active Active
- 2019-10-22 EP EP19805797.8A patent/EP3870296A1/en active Pending
- 2019-10-22 KR KR1020217015135A patent/KR20210095143A/en unknown
- 2019-10-22 SG SG11202104086PA patent/SG11202104086PA/en unknown
- 2019-10-22 AU AU2019364352A patent/AU2019364352A1/en active Pending
- 2019-10-22 MA MA053983A patent/MA53983A/en unknown
- 2019-10-22 WO PCT/US2019/057362 patent/WO2020086533A1/en active Application Filing
- 2019-10-22 CN CN201980082985.8A patent/CN113195055A/en active Pending
-
2021
- 2021-04-19 IL IL282433A patent/IL282433A/en unknown
- 2021-04-21 PH PH12021550887A patent/PH12021550887A1/en unknown
-
2022
- 2022-11-17 US US17/989,237 patent/US12030869B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL282433A (en) | 2021-06-30 |
| MA53983A (en) | 2021-12-15 |
| CA3117449A1 (en) | 2020-04-30 |
| JP2022508953A (en) | 2022-01-19 |
| US11560370B1 (en) | 2023-01-24 |
| BR112021007602A2 (en) | 2021-07-27 |
| WO2020086533A1 (en) | 2020-04-30 |
| TW202028190A (en) | 2020-08-01 |
| US20240150324A1 (en) | 2024-05-09 |
| MX2021004580A (en) | 2021-09-08 |
| CN113195055A (en) | 2021-07-30 |
| EP3870296A1 (en) | 2021-09-01 |
| KR20210095143A (en) | 2021-07-30 |
| US12030869B2 (en) | 2024-07-09 |
| PH12021550887A1 (en) | 2022-02-21 |
| AU2019364352A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282433A (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
| HK1257734A1 (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | |
| EP4067347C0 (en) | Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer | |
| HUE057665T2 (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| GB201720163D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B | |
| IL275321A (en) | Compounds for treatment of diseases related to dux4 expression | |
| IL265062B (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| IL276482A (en) | Compounds for the treatment of pain | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL279497A (en) | Treatment of proteinuria | |
| EP3773659A4 (en) | Methods for treatment of hbv infection | |
| EP3846820A4 (en) | Cyclic sulfamide compounds for treatment of hbv | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| IL273364A (en) | Mpges-1 inhibitor for the treatment of osteoarthritis pain | |
| IL260405A (en) | None-abusive derivatives of ritalin | |
| GB201714772D0 (en) | Dosage forms of therapeutic compounds |